Search

Displaying results 2961 - 2970 of 10000 in total
  1. Drug

    Zinc sulfate, unspecified form

    go.drugbank.com/drugs/DB14548
    Approved

    Zinc sulfate is a common zinc supplement in parenteral nutrition.[A216916,L12888]

    Mixtures: i-Drops ARTIFICIAL TEARS
  2. Drug

    Gemigliptin

    go.drugbank.com/drugs/DB12412
    Investigational

    Gemigliptin is under investigation in Type 2 Diabetes Mellitus. Gemigliptin has been investigated for the treatment of Cancer and Cisplatin Adverse Reaction.

    Categories: DPP-IV Inhibitors, Drugs Used in Diabetes
  3. Drug

    Succinic acid

    go.drugbank.com/drugs/DB00139
    ApprovedInvestigationalNutraceutical

    It is also used in foods as a sequestrant, buffer, and a neutralizing agent. … A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters.

  4. Drug

    Oxymorphone

    go.drugbank.com/drugs/DB01192
    ApprovedVet approved

    It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092).

    Products: Numorphan Injection 1.5mg/ml
  5. Drug

    Regadenoson

    go.drugbank.com/drugs/DB06213
    ApprovedInvestigational

    Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.

  6. Drug

    Nafarelin

    go.drugbank.com/drugs/DB00666
    ApprovedInvestigational

    Nafarelin has been used in the treatments of central precocious puberty and endometriosis. … Nafarelin is a potent synthetic agonist of gonadotropin-releasing hormone with 3-(2-naphthyl)-D-alanine substitution at residue 6.

    Products: Synarel Nas Sol 2mg/ml
  7. Drug

    Tafamidis

    go.drugbank.com/drugs/DB11644
    ApprovedInvestigational

    [A189717] Tafamidis is structurally similar to diflusinal.[A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]

  8. Drug

    Dalfopristin

    go.drugbank.com/drugs/DB01764
    Approved

    It is not effective against Enterococcus faecalis infections. … Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.

  9. Drug

    Trapidil

    go.drugbank.com/drugs/DB09283
    Experimental

    Trapidil, a platelet-derived growth factor antagonist, was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney disease.

    Categories: Vasodilators Used in Cardiac Diseases
  10. Drug

    Lemborexant

    go.drugbank.com/drugs/DB11951
    ApprovedInvestigational

    Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. … [L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to